Novel Oral Anticoagulant and Efficacy on Atrial Fibrillation Patients
Atrial fibrillation is the most common Cardiac arrhythmia and the third major cause of death in elderly. Atrial fibrillation is considered as a major cause for stroke in UK and England. Atrial fibrillation (AF) is associated with stroke due to thromboembolism. Atrial fibrillation is affecting more than 600,000 people all over world. Warfarin is the first anticoagulant which was used for atrial fibrillation patient. There is need for proper patient care and safety regulation while using warfarin, since there is risk of blood clotting in more for patients using warfarin. Novel Oral Anticoagulants (NOACs) which are new class of anticoagulant drugs and used instead of warfarin due to less risk of blood clotting in patients. Apixaban, Dabigatran and Rivaroxaban are most commonly used NOACs drugs. This review article gives complete description about efficacy and comparative use of Anti-coagulants and Novel Oral Anticoagulants in Atrial fibrillation patients having risk of stroke. It mainly focuses on use of NOACs in place of warfarin which is safe to use.